• Almirall, LLC v. Acrux DDS Pty. Ltd. (2:2021-cv-11948) (D. NJ) Representing Defendant Acrux in patent litigation over ANDA to make a generic version of Almirall’s topical acne product Aczone (dapsone).  Pending.
  • Dicerna Pharms, Inc. v. Alnylam Pharms, Inc. (17-11466) (D. Mass) Represented Dicerna in antitrust litigation with its competitor Alnylam in the RNA interference field.  Settled favorably for Dicerna. 
  • Alnylam Pharms, Inc. v. Dicerna Pharms, Inc. (15-04126-EPL) (Mass. Sup. Ct.) Represented Dicerna in trade secret litigation regarding RNA interference technology.  Settled before trial favorably for Dicerna.
  • Inter Partes Review Nos. 2015-01976, -01980 and -01981.  Invalidated all claims for Petitioner Amneal Pharma in IPR of U.S. Patent Nos. 8,232,250, 8,399,413 and 8,969,302, listed in the FDA Orange Book for Teva’s MS product Copaxone.
  • In re Copaxone 40 mg Consolidated Cases, 14-CV-01171 (GMS) (D.Del.)  Successful invalidation of all claims in patent infringement action regarding Amneal’s ANDA to make a generic version of Teva’s MS product Copaxone 40 mg.
  • Eli Lilly & Co. et al. v. Amneal Pharms LLC (14-02025-SEB) (SD IN) Represented Amneal in full litigation, including trial, in patent infringement action over patents related to Lilly’s testosterone replacement product Axiron.
  • Inter Partes Review Nos. 2014-01041 and -01043, representing Petitioner Metrics, Inc. in IPR of U.S. Patent Nos. 8,129,431 and 8,669,290, listed in the FDA Orange Book for Senju Pharma’s ophthalmic product Prolensa.  Settled favorably for Metrics.
  • Senju Pharms Co., Ltd., et al. v. Metrics, Inc. et al. (14-3962-JBS)(D. NJ) Represented Defendant Metrics in patent litigation over ANDA to make a generic version of Senju’s ophthalmic product Prolensa.  Settled favorably for Metrics.
  • Depomed, Inc. et al. v. Actavis Elizabeth et al. (13-04507-CCC) (D. NJ) Full trial.  Represented Actavis in patent litigation over ANDAs for Janssen’s pain products Nucynta® and Nucynta ER.  Successful ruling of non-infringement for Actavis.
  • Warner-Chilcott Co. LLC, et al. v. Ranbaxy, Inc., et al. (12-2474-FSH) (D. NJ) Patent litigation regarding Ranbaxy’s ANDA for Warner-Chilcott’s osteoporosis product Atelvia (risedronate).
  • Avanir Pharms, Inc., et al. v. Wockhardt, Ltd., et al. (11-704-LPS) (D. Del.)  Full trial.  Patent infringement action regarding Wockhardt’s ANDA to make a generic version of Avanir’s PBA product Nuedexta.
  • King Pharms, Inc., et al. v. Actavis Inc., et al. (07-05041-GEB) (D. N.J.).  Full trial.  Represented Actavis in patent action over ANDA for King’s pain product Avinza (morphine sulfate).  Settled successfully after trial.
  • Sepracor Inc. v. Teva Pharms USA, Inc., et al. (09-1302-DMC)(D NJ). Patent litigation regarding Wockhardt’s ANDA for Sepracor’s insomnia product Lunesta (eszopiclone).  Settled favorably for Wockhardt. 
  • Aventis Pharms S.A. et al. v. Apotex Inc. et al. (08-496-GMS) (D. Del.). Patent infringement action regarding Apotex’s ANDA for Sanofi-Aventis’ anti-cancer product TAXOTERE (docetaxel).  Two-week trial.  Invalidated all claims and Sanofi’s patents ruled unenforceable.
  • Medicis Pharms Corp. v. Sandoz, Inc. et al. (09-033-JJF) (D Del.). Patent infringement action regarding Sandoz’s ANDA for Medicis’s acne product Solodyn (minocycline hydrochloride).  Settled favorably for Sandoz.
  • Endo Pharms Inc. et al. v. Sandoz, Inc. (08-534 and 08-970 – KSH) (D Del.). Patent infringement action regarding Sandoz’s ANDA for Endo’s pain product Opana ER (oxymorphone hydrochloride).  Settled favorably for Sandoz.
  • Aventis Pharms, Inc. et al. v. Barr Labs, Inc. et al. (01-3627-JAG) (D NJ). Patent infringement action regarding Barr Laboratories’ ANDA for Aventis’s allergy product Allegra (fexofenadine hydrochloride).  Successful opposition to preliminary injunction and successful launch at risk for Barr.
  • Eli Lilly & Co. v. Barr Labs, Inc. (02-1844-SEB) (SD IN). Patent infringement action regarding Barr’s ANDA for Lilly’s osteoporosis product Evista (raloxifene hydrochloride).
  • Ferring B.V. et al. v. Barr Labs, Inc. (02-9851) (SD NY). Patent infringement action regarding Barr Labs’ ANDA for Ferring’s urinary incontinence product DDAVP (desmopressin acetate).  Successfully rendered patent unenforceable.
  • Bayer Schering AG, et al. v. Barr Labs, Inc. (05-2308-JPS)(D.N.J.) Patent infringement action regarding Barr’s ANDA for Bayer’s contraceptive Yasmin (drospirenone).